Safety, Tolerability and Efficacy Study of ARCT-032 in People With Cystic Fibrosis (NCT06747858)
A Phase 2, Open-label, Multiple Ascending-Dose Study to Evaluate the Safety, Tolerability and Efficacy of ARCT-032 in People With Cystic Fibrosis
🩺 Plain-English Summary (8th-Grade Level)
ARCT-032-02 is a Phase 2, open-label, multicenter, multiple-ascending dose study of ARCT-032 in adults with CF who are not eligible for CFTR modulator therapy or are not taking CFTR modulators due to drug intolerance, poor response, or lack of access to modulators.
Who can join: Review the eligibility criteria below.
Location: University of Arizona — Tucson, Arizona
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (13 Sites)
- University of Arizona — Tucson, Arizona
- University of Arkansas for Medical Sciences — Little Rock, Arkansas
- Children's Hospital of Los Angeles — Los Angeles, California
- Children's National Hospital — Washington D.C., District of Columbia
- Joe DiMaggio Children's Hospital — Hollywood, Florida
- The Cystic Fibrosis Institute — Northfield, Illinois
- Boston Children's Hospital — Boston, Massachusetts
- Washington University School of Medicine — St Louis, Missouri
- Cleveland Clinic Foundation — Cleveland, Ohio
- Medical University of South Carolina — Charleston, South Carolina
- Vanderbilt University Medical Center — Nashville, Tennessee
- UT Health San Antonio — San Antonio, Texas
- Seattle Children's Hospital — Seattle, Washington
📞 Contact the Study Coordinator
Phone: (858) 900-2660
Email: CFclinicaltrials@arcturusrx.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Cystic Fibrosis
- Genetic Modifiers of Cystic Fibrosis (CF) Liver Disease — Chapel Hill, North Carolina
- Evaluation of VX-121/Tezacaftor/Deutivacaftor in Cystic Fibrosis (CF) Participants 1 Through 11 Years of Age — Orange, California
- Hyperpolarized Imaging for New Treatments — Cincinnati, Ohio
- Monitoring Response to Orkambi in Cystic Fibrosis Lung Disease by Inhaled Xenon MRI — Cincinnati, Ohio
- Evaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA in Cystic Fibrosis Participants 12 Months of Age and Older — Nedlands,
- Non-contrast Lung Perfusion Mapping Applied for New Insights in Cystic Fibrosis — Cincinnati, Ohio
Explore by condition: All Cystic Fibrosis clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.